Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19
Daniel A. Goldstein, Mark J. Ratain, Leonard B. Saltz
Abstract
cology or medicine-and consider if we should do it even if there is no pandemic. We believe this is an opportunity to choose wisely, be thoughtful, and critically appraise the evidence for everything we do as physicians.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)DosingPembrolizumab2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BetacoronavirusMEDLINEInternal medicineVirologyCancerOutbreakImmunotherapyPolitical scienceDiseaseInfectious disease (medical specialty)LawCancer Immunotherapy and BiomarkersCOVID-19 and healthcare impactsCancer, Stress, Anesthesia, and Immune Response